Literature DB >> 28359102

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.

Livia Lamartina1, Isabelle Borget2, Haitham Mirghani3, Abir Al Ghuzlan4, Amandine Berdelou1, François Bidault5, Désirée Deandreis1, Eric Baudin1, Jean-Paul Travagli3, Martin Schlumberger1, Dana M Hartl3, Sophie Leboulleux1.   

Abstract

Background: Persistent/recurrent disease in the neck is frequent in patients with differentiated thyroid cancer (DTC). Objective: Assess efficacy, safety, and prognostic factors of first neck reoperation in DTC.
Methods: Retrospective study of consecutive patients undergoing neck reoperation for recurrent/persistent DTC in a referral cancer center. Response after reoperation was defined according to the 2015 American Thyroid Association guidelines. Findings: One hundred sixty-one DTC patients were enrolled (64% females, median age 35 years, 96% papillary DTC). Initial stage was pT3 in 43% and pT4 in 10%, pN1 in 74%. Aggressive histology was present in 25% of the patients, in both primary and persistent/recurrent tumor. Four patients had no malignancy in the reoperative specimen, and 1 patient died due to postoperative hematoma and was excluded from further analysis. Following reoperation, 15 patients (10%) had persistent structural disease, 16 (10%) had biochemical incomplete response, 26 (17%) had indeterminate response, and 99 (63%) had complete response (CR), among whom 24 relapsed later. After a median follow-up of 5 years, only 83 patients (53%) had CR without the need for further treatments. The rate of permanent complications was: hypoparathyroidism 2%, laryngeal nerve palsy 0.6%, other 6%. Age ≥45 years, aggressive histology, and lymph node ratio ≥0.6 at initial surgery were independent risk factors for incomplete response after reoperation. Male sex, aggressive histology, and ≥10 metastases at reoperation were independent risk factors of secondary relapse following CR achieved with reoperation.
Conclusion: A careful risk-benefit analysis should guide surgical decision, particularly in patients with risk factors for incomplete response.
Copyright © 2017 by the Endocrine Society

Entities:  

Mesh:

Year:  2017        PMID: 28359102     DOI: 10.1210/jc.2016-3284

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors.

Authors:  Hiroyuki Iwasaki; Haruhiko Yamazaki; Hirotaka Takasaki; Nobuyasu Suganuma; Rika Sakai; Hirotaka Nakayama; Shinsuke Hatori; Soji Toda; Katsuhiko Masudo
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

2.  Treatment-Free Survival in Patients With Differentiated Thyroid Cancer.

Authors:  Mousumi Banerjee; David Reyes-Gastelum; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

Review 3.  Current practice in patients with differentiated thyroid cancer.

Authors:  Martin Schlumberger; Sophie Leboulleux
Journal:  Nat Rev Endocrinol       Date:  2020-12-18       Impact factor: 43.330

Review 4.  UPDATED UNDERSTANDING OF THE MOLECULAR TARGETS OF RADIOIODINE IN DIFFERENTIATED THYROID CANCER.

Authors:  Y Zhang; W Zou; X Zhu; L Jiang; C Gui; Q Fan; Y Tu; J Chen
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

5.  Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.

Authors:  Matthew L Hung; James X Wu; Ning Li; Masha J Livhits; Michael W Yeh
Journal:  JAMA Surg       Date:  2018-12-01       Impact factor: 14.766

6.  A Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer.

Authors:  Hai-Long Tan; Bo-Qiang Huang; Gui-You Li; Bo Wei; Pei Chen; Hui-Yu Hu; Mian Liu; Deng-Jie Ou-Yang; Qiong Yang; Zi-En Qin; Qi-Man Shi; Ning Li; Peng Huang; Shi Chang
Journal:  Int J Endocrinol       Date:  2021-06-30       Impact factor: 3.257

Review 7.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

8.  Comparison of endoscopic thyroidectomy via a modified axillo-breast approach with the conventional breast approach for treatment of unilateral papillary thyroid microcarcinoma.

Authors:  KangNan Mo; Ming Zhao; KeJing Wang; JiaLei Gu; Zhuo Tan
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

9.  Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.

Authors:  Renaud Ciappuccini; Natacha Heutte; Audrey Lasne-Cardon; Virginie Saguet-Rysanek; Camille Leroy; Véronique Le Hénaff; Dominique Vaur; Emmanuel Babin; Stéphane Bardet
Journal:  BMC Cancer       Date:  2020-08-14       Impact factor: 4.430

10.  Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).

Authors:  Hiroshi Miura; Kazuhiko Sakaguchi; Yuko Okada; Tomoko Yamada; Natsu Otowa-Suematsu; Anna So; Hisako Komada; Yushi Hirota; Takeshi Ohara; Yasuo Kuroki; Kenta Hara; Tomokazu Matsuda; Minoru Kishi; Akihiko Takeda; Kazuki Yokota; Yoshikazu Tamori; Wataru Ogawa
Journal:  J Diabetes Investig       Date:  2019-03-28       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.